Netcapital Amends Toxic Notes, Secures Nasdaq Reprieve Through February 2027
NCPL sits 29% above its 52-week low of $0.312.
Summary
Netcapital amended three toxic convertible notes with Vanquish Funding Group, adding a Nasdaq cap and floor price, and received a 180-day Nasdaq extension to regain the $1.00 minimum bid price. The amendments slightly limit but do not eliminate the risk of massive dilution upon default, while the Nasdaq reprieve buys time against a backdrop of an SEC fraud complaint and going-concern doubts.
Key Events · Financing and Capital Events · NCPL
-
Toxic Note Amendments
Three convertible notes with Vanquish Funding Group (original principal $51,750, $92,800, and $182,120) were amended to add a 19.99% Nasdaq conversion cap, a $0.10 floor price for the first six months, and a 4.99% beneficial ownership blocker. The conversion price remains 65% of the lowest 20-day trading price upon default.
-
Nasdaq Extension Granted
Nasdaq granted an additional 180-day compliance period until February 1, 2027, to regain the $1.00 minimum bid price requirement. The company did not regain compliance during the initial 180-day period that ended August 3, 2026.
-
Reverse Split Contingency
The company intends to effect a reverse stock split if necessary to regain compliance, but must complete it by January 20, 2027 (10 business days before the deadline). Failure to regain compliance will result in delisting, with no automatic stay of suspension upon appeal.
-
SEC Fraud Complaint Overhang
The SEC filed a civil fraud complaint on August 10, 2026, alleging the company fabricated nearly $14 million in revenue. This regulatory action compounds the going-concern risk and could accelerate defaults under the amended notes.
Analysis · NCPL · Finance
Netcapital amended three convertible notes with Vanquish Funding Group, adding a 19.99% Nasdaq cap, a $0.10 floor price for six months, and a 4.99% ownership blocker — terms that slightly limit but do not eliminate the deeply dilutive conversion mechanics (65% of the lowest 20-day price). Separately, Nasdaq granted an additional 180 days to cure the $1.00 bid price deficiency, pushing the deadline to February 1, 2027. The company remains in a precarious position: the note amendments are a band-aid on toxic financing that can still trigger massive dilution upon default, while the Nasdaq extension buys time but does not solve the underlying business crisis — the SEC fraud complaint alleging fabricated revenue and the going-concern warning remain unresolved.
At the time of this filing, NCPL was trading at $0.40 on NASDAQ in the Finance sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.31 to $3.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.